Monitoring sarcoma patients using exosomes
Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC)
This study looks at tiny particles in the blood of sarcoma patients to see if they can help us understand how the cancer grows and responds to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 34 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Georges Francois Leclerc Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Besançon and 2 other locations) |
| Trial ID | NCT03800121 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze exosomes in patients diagnosed with sarcoma to better understand their role in tumor progression and metastasis. By quantifying exosomes and examining their protein and RNA content, the study seeks to establish correlations between exosome levels and the stage of the disease, as well as treatment responses. Blood samples will be collected from patients with localized, metastatic, or locally advanced sarcoma before and after treatment to assess changes in exosome concentration and composition.
Who should consider this trial
Good fit: Ideal candidates include men and women aged 18 and older who are newly diagnosed with localized, metastatic, or locally advanced soft tissue sarcoma.
Not a fit: Patients with synchronous tumors, those with a history of other cancers within the last five years, or those unable to undergo medical follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and treatment strategies for sarcoma patients based on exosome analysis.
How similar studies have performed: While the use of exosomes in cancer monitoring is an emerging field, this specific approach in sarcoma has not been extensively tested, making it a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Men and women newly diagnosed with localized, metastatic or locally advanced soft tissue sarcoma 2. Previous treatment of the disease with chemotherapy, radiotherapy or surgery is allowed if it has been completed for more than 12 months at the time of inclusion. 3. For metastatic or locally advanced (inoperable) sarcoma, patients for whom first-line metastatic chemotherapy is indicated. 4. Age ≥18 years 5. Affiliation to a social security scheme 6. Patients who signed informed consent to participate in the study Exclusion Criteria: Patients who meet at least one of the following criteria will not be eligible: 1. Patient with another synchronous tumor, 2. Patient with sarcoma in irradiated territory 3. Patient with a history of cancer other than sarcoma in the 5 years preceding the diagnosis of sarcoma 4. Patient unable to undergo medical follow-up for geographical, social or psychological reasons, 5. Person benefiting from a protection system for adults (including guardianship and trusteeship), 6. Serology HIV and / or HBV and / or HCV positive. 7. Pregnant or lactating woman. 8. Patients unable to understand, read and / or sign informed consent.
Where this trial is running
Besançon and 2 other locations
- CHU de Besançon — Besançon, France (Recruiting)
- Centre Georges François Leclerc — Dijon, France (Recruiting)
- CHU de Poitiers — Poitiers, France (Recruiting)
Study contacts
- Study coordinator: Alice HERVIEU
- Email: ahervieu@cgfl.fr
- Phone: 03 80 73 75 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.